Orchestra BioMed Holdings Inc. (OBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Orchestra BioMed Holdings Inc. (OBIO) has a cash flow conversion efficiency ratio of -0.435x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.17 Million) by net assets ($50.97 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Orchestra BioMed Holdings Inc. net asset quality index to measure how much of total assets are equity-financed.
Orchestra BioMed Holdings Inc. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Orchestra BioMed Holdings Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check OBIO cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Orchestra BioMed Holdings Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Orchestra BioMed Holdings Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Exicom Tele-Systems Limited
NSE:EXICOM
|
-0.096x |
|
LTC Co.Ltd
KQ:170920
|
0.043x |
|
Ritek Corp
TW:2349
|
-0.009x |
|
Union Insurance Co Ltd
TW:2816
|
0.029x |
|
Y.U.D. Yangtze River Investment Industry Co Ltd
SHG:600119
|
-0.060x |
|
Jasuindo Tiga Perkasa Tbk
JK:JTPE
|
-0.046x |
|
EPACK Durable Limited
NSE:EPACK
|
-0.218x |
|
DFI Inc
TW:2397
|
0.038x |
Annual Cash Flow Conversion Efficiency for Orchestra BioMed Holdings Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Orchestra BioMed Holdings Inc. from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Orchestra BioMed Holdings Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $63.38 Million | $-48.96 Million | -0.773x | +49.64% |
| 2024-12-31 | $32.96 Million | $-50.56 Million | -1.534x | -126.29% |
| 2023-12-31 | $68.04 Million | $-46.13 Million | -0.678x | -21.59% |
| 2022-12-31 | $52.53 Million | $-29.29 Million | -0.558x | -304.40% |
| 2021-12-31 | $-71.23 Million | $-19.43 Million | 0.273x | -49.43% |
| 2020-12-31 | $-48.54 Million | $-26.18 Million | 0.539x | -- |
About Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develop… Read more